Keyphrases
Non-small Cell Lung Cancer (NSCLC)
70%
EGFR mutation
68%
Lung Cancer
54%
Non-small Cell Lung Cancer Patients
40%
Erlotinib
35%
Chemotherapy
35%
Epidermal Growth Factor Receptor
35%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
33%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
29%
Progression-free Survival
25%
Lung Adenocarcinoma
19%
Breast Cancer Susceptibility Gene 1 (BRCA1)
17%
Cisplatin
17%
Overall Survival
16%
Docetaxel
15%
Lung Cancer Patients
14%
Gefitinib
14%
Small Cell Lung Cancer
14%
MRNA Expression
14%
Tumor
12%
Targeted Therapy
11%
Phase II Trial
11%
Confidence Interval
10%
Adverse Events
10%
Stage IV Non-small Cell Lung Cancer
10%
Programmed Death-ligand 1 (PD-L1)
9%
Hazard Ratio
8%
Osimertinib
8%
Stage III Non-small Cell Lung Cancer
8%
Phase II Study
8%
Clinical Practice Guidelines
8%
Median Survival
8%
T790M mutation
7%
Acquired Resistance
7%
Adenocarcinoma
7%
Tyrosine Kinase Inhibitor
7%
Spain
7%
Gemcitabine
7%
Nivolumab
7%
Monotherapy
7%
Solid Tumors
7%
Randomized Phase II Trial
7%
Durvalumab
6%
Immune Checkpoint Inhibitors
6%
Afatinib
6%
Exon 19
6%
Activating mutation
6%
MRNA Level
6%
Immunohistochemistry
6%
Response Prediction
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
81%
Lung Cancer
67%
Chemotherapy
43%
Erlotinib
29%
Progression Free Survival
28%
Cisplatin
23%
Overall Survival
21%
Neoplasm
21%
Disease
20%
Epidermal Growth Factor Receptor Kinase Inhibitor
19%
Malignant Neoplasm
19%
Messenger RNA
17%
Adverse Event
15%
Docetaxel
14%
Lung Adenocarcinoma
14%
Small Cell Lung Cancer
13%
Immunotherapy
13%
Solid Malignant Neoplasm
11%
Protein Tyrosine Kinase Inhibitor
10%
Osimertinib
9%
Biological Marker
9%
Gefitinib
9%
Clinical Trial
8%
Nivolumab
7%
Monotherapy
6%
Gemcitabine
6%
Durvalumab
6%
Breast Cancer
6%
Anticarcinogen
6%
Chemoradiation Therapy
6%
Afatinib
6%
Receptor
6%
Immune Checkpoint Inhibitor
5%
Protein Tyrosine Kinase
5%
Adenocarcinoma
5%
SARS Coronavirus
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
68%
Epidermal Growth Factor Receptor
59%
Lung Cancer
49%
Chemotherapy
30%
Neoplasm
18%
Small Cell Lung Cancer
18%
Epidermal Growth Factor Receptor Kinase Inhibitor
15%
Immunotherapy
15%
Overall Survival
13%
Cisplatin
12%
Progression Free Survival
11%
Diseases
10%
Malignant Neoplasm
10%
Erlotinib
9%
Lung Adenocarcinoma
9%
Messenger RNA
9%
Adverse Event
8%
Clinical Guideline
8%
Breast Cancer
8%
Programmed Death-Ligand 1
7%
Targeted Therapy
7%
Oncology
7%
Exon
7%
Nivolumab
7%
Biological Marker
6%
Solid Malignant Neoplasm
6%
Durvalumab
6%
Non-Small Cell Lung Cancer
6%
Immune Checkpoint Inhibitor
6%
Programmed Cell Death
6%
Human Immunodeficiency Virus
5%
Gefitinib
5%
Docetaxel
5%
Ganglioglioma
5%
Protein Tyrosine Kinase
5%
Tyrosine-Kinase Inhibitor
5%
Hazard Ratio
5%
Radiation Therapy
5%
Primary Tumor
5%
